Ann Hanham Insider Profile

4 Followers
Ann Hanham, Director at Endocyte, holds 46.62K shares in SCYNEXIS (Ticker: SCYX), holds 7.30K shares in HTG Molecular Diagnostics (Ticker: HTGMQ), holds 2.25K shares in Endocyte (Ticker: ECYT).
tipranks
Ann Hanham

Ann Hanham
Endocyte (ECYT)
Director

Ranked #72,504 out of 99,172 Corporate Insiders

Profitable Transactions

0%
0 out of 2 Profitable Transactions

Average Return

-29.10%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$11M
99.41%
0.59%
<0.01%
A breakdown of Ann Hanham's holdings

Insider Roles

Gyre Therapeutics
(GYRE)
Director
SCYNEXIS
(SCYX)
Director
HTG Molecular Diagnostics
(HTGMQ)
Director
Roles that Ann Hanham holds in companies

Most Profitable Insider Trade

Stock:
SCYNEXIS
(SCYX)
Rating:Informative Buy
Date:Dec 23, 2020 - Dec 23, 2021
Return:-4.20%
The most profitable trade made by Ann Hanham

Ann Hanham's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
ECYT
Endocyte
May 05, 2017
Uninformative Buy
$53.98K
HTG Molecular Diagnostics
Aug 16, 2019
Director
Uninformative Buy
$87.65
SCYNEXIS
Jun 21, 2024
Director
Uninformative Buy
$66.20K
Gyre Therapeutics
Director
$11.21M
BMTI
Biomimetic Therapeutics
List of latest transactions for each holding click on a transaction to see Ann Hanham's performance on stock

Ann Hanham insider profile FAQ

What is the percentage of profitable transactions made by Ann Hanham?
The percentage of profitable transactions made by Ann Hanham is 0%.
    What is the average return per transaction made by Ann Hanham?
    The average return per transaction made by Ann Hanham is -29.10%.
      What stocks does Ann Hanham hold?
      Ann Hanham holds: ECYT, HTGMQ, SCYX, GYRE, BMTI stocks.
        What was Ann Hanham’s latest transaction?
        Ann Hanham latest transaction was an Uninformative Buy of ―.
          What was Ann Hanham's most profitable transaction?
          Ann Hanham’s most profitable transaction was an Informative Buy of SCYX stock on December 23, 2020. The return on the trade was -4.20%.
            What is Ann Hanham's role in Endocyte?
            Ann Hanham's role in Endocyte is Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.